TLR4 and COVID-19: Our result also comes in accordance with a previous clinical study, which was conducted by Khodir et al. on patients with COVID-19 and demonstrated the potential role of nifuroxazide in attenuating sepsis-induced systemic inflammation and multiple organ failure through interruption of TLR-4/inflammasome NLRP3/IL-1β signaling [24].